Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on X:
“EVERGREEN study led by Diogo Martins Branco.
A quasi-experimental analysis of >200 pts, showed that Everolimus+ET increased PFS (aHR 0.68, CI 0.47-0.99) vs ET alone after progression on CDK4/6i
EVE had higher efficacy when combined with AI, increased BMI, IDC, and longer prior CDK4/6 Treatment.”
Source: Guilherme Nader Marta/X